Updated Jul 16, 2026
Houston John G has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $466K.
John G. Houston is a director at Arvinas, Inc., a biotechnology company focused on developing therapies for cancer and other diseases through targeted protein degradation. His experience in the biotechnology sector contributes to the strategic direction of the company.
| Role | Insider |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-03 | ARVN | ARVINAS, INC. | S — Open-market sale | 11.8K | $13.14 | $155K |
| 2026-03-03 | ARVN | ARVINAS, INC. | S — Open-market sale | 18.8K | $13.24 | $249K |
| 2026-03-03 | ARVN | ARVINAS, INC. | S — Open-market sale | 4.7K | $13.24 | $62K |
John G. Houston is a director at Arvinas, Inc., a biotechnology company focused on developing therapies for cancer and other diseases through targeted protein degradation. His experience in the biotechnology sector contributes to the strategic direction of the company.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 3 open-market sales ($466K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Houston John G profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.